Clinical Trials
9 trialsNCT02257619 2026-04-21
Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
Incyte Corporation
Phase 2 Terminated
NCT04629508 2025-09-02
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
Incyte Corporation
Phase 2 Completed
NCT05364762 2025-05-30
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03425006 2023-09-13
Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer
University of Pennsylvania
Phase 2 Terminated
NCT03144687 2022-06-16
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
Incyte Corporation
Phase 2 Completed
NCT01633372 2021-08-30
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
Incyte Corporation
Phase 2 Completed
NCT04127721 2020-10-29
Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02355431 2019-03-08
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Incyte Corporation
Phase 2 Withdrawn
NCT02456675 2018-01-12
INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma
Incyte Corporation
Phase 2 Terminated